Kiyatec

KIYATEC Utilizes Its Proprietary Ex Vivo 3D Cell Culture Technology Platform to Accurately Model and Predict Responses to Approved and Investigational Cancer Drugs for Solid Tumors.Drug Development Services: KIYATEC collaborates with leading biopharmaceutical companies to unlock response dynamics (ex vivo efficacy) for their investigational cancer drug candidates in preclinical testing and subsequent clinical trials.Clinical Testing Services (CLIA-Certified Laboratory): In 2019, KIYATEC released analytical validation of the assay and clinical evidence of its predictive performance. Currently, KIYATEC is further validating clinical assays that predict drug responses and conducting investigator-initiated studies on ovarian cancer, high-grade gliomas, breast cancer, and rare tumors.